Filing Flows › Macrogenics (MGNX) › Q1 2026 › vs Q4 2025
Macrogenics (MGNX) Q1 2026 vs Q4 2025 (quarter over quarter)
Macrogenics's revenue fell $20.5M (-50%) from $41.2M in Q4 2025 to $20.8M in Q1 2026.
Macrogenics, Q1 2026: revenue $20.8M (+58% year over year), operating margin -161.0%, net loss $36.8M, operating cash flow −$35.8M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $20.8M | $41.2M | −$20.5M | -50% |
| Net loss | $36.8M | $14.2M | $22.6M | +160% |
| Costs & expenses | $57.5M | $56.2M | $1.4M | +2% |
| Operating costs | $54.2M | $53.3M | $890K | +2% |
| Interest & other, net | $3.3M | $2.8M | $500K | +18% |
| Research & development | $35.0M | $34.0M | $1.0M | +3% |
| General & admin | $9.7M | $9.2M | $475K | +5% |
| Other operating costs | $9.5M | $10.1M | −$585K | -6% |
| Operating cash sources | $40.1M | −$38.7M | $78.8M | — |
| Depreciation & amortization | $1.7M | $1.7M | −$18K | -1% |
| Share-based compensation | $2.6M | $2.7M | −$15K | -0.6% |
| Cash used in operations | $35.8M | −$43.0M | $78.8M | — |
| Net loss absorbed | $36.8M | $14.2M | $22.6M | +160% |
| Working capital & other | $3.4M | −$52.8M | $56.2M | — |
Questions
How much did Macrogenics's revenue grow quarter over quarter in Q1 2026?
Macrogenics's revenue fell $20.5M (-50%) from $41.2M in Q4 2025 to $20.8M in Q1 2026.